|
rs2285489
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We retrospectively examined whether <i>ADAMTS13</i> rs2285489 affected the transplant outcomes in a cohort of 281 patients who underwent unrelated human leukocyte antigen (HLA)-matched bone marrow transplantation for hematologic malignancies.
|
30626079 |
2019 |
|
rs3921
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This study retrospectively examined the impact of a single nucleotide variation (rs3921, +1642C>G) in the CXCL10 gene on transplant outcomes in a cohort of 652 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies.
|
23291247 |
2013 |
|
rs770692189
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis.
|
17517660 |
2007 |
|
rs267606706
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.
|
23696637 |
2013 |
|
rs387906664
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
CBL linker region and RING finger mutations lead to enhanced granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling via elevated levels of JAK2 and LYN.
|
23696637 |
2013 |
|
rs757874631
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We analyzed 77 samples from hematologic malignancies, identifying a somatic mutation in CBL (p.C381R) in one patient with T-ALL that was associated with a uniparental disomy at the CBL locus and a germline heterozygous mutation in one patient with JMML.
|
22591685 |
2012 |
|
rs1800023
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We retrospectively examined the impact of the CCR5 variation (rs1800023, -2086A>G) on transplant outcomes in a cohort of 329 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies through the Japan Marrow Donor Program.
|
28487238 |
2017 |
|
rs13347
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In conclusion, our results indicate that among investigated single nucleotide polymorphisms (SNPs), only CD44 rs13347 has an impact on the efficacy of HSCs mobilization in patients with hematologic malignancies.
|
24680978 |
2014 |
|
rs767464424
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three out of 14 (21.4 %) C57BL/6J mice transplanted with FLT3-N676K-transduced primary hematopoietic progenitor cells developed acute leukemia (latency of 68, 77, and 273 days), while no hematological malignancy was observed in the control groups including FLT3-ITD.
|
26891877 |
2016 |
|
rs777017502
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three out of 14 (21.4 %) C57BL/6J mice transplanted with FLT3-N676K-transduced primary hematopoietic progenitor cells developed acute leukemia (latency of 68, 77, and 273 days), while no hematological malignancy was observed in the control groups including FLT3-ITD.
|
26891877 |
2016 |
|
rs1057519802
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1.
|
18971950 |
2009 |
|
rs1057520014
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
FMS mutations in myelodysplastic, leukemic, and normal subjects.
|
2406720 |
1990 |
|
rs121913390
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
FMS mutations in myelodysplastic, leukemic, and normal subjects.
|
2406720 |
1990 |
|
rs121913393
|
|
G |
0.700 |
GeneticVariation |
CLINVAR |
FMS mutations in myelodysplastic, leukemic, and normal subjects.
|
2406720 |
1990 |
|
rs1801271
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
FMS mutations in myelodysplastic, leukemic, and normal subjects.
|
2406720 |
1990 |
|
rs1801271
|
|
A |
0.700 |
GeneticVariation |
CLINVAR |
FMS mutations in myelodysplastic, leukemic, and normal subjects.
|
2406720 |
1990 |
|
rs1801157
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Several recent studies have shown that <i>SDF1</i>-3'A polymorphism (rs1801157) is associated with susceptibility to hematological malignancy, but published studies' results are disputed.
|
28352190 |
2017 |
|
rs3745274
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This study demonstrates for the first time that the presence of the CYP2B6 G516T mutation increases the rate of 4-OH-CPA formation in patients with hematological malignancies.
|
16183265 |
2006 |
|
rs724159945
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.
|
25581430 |
2015 |
|
rs724159946
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.
|
25581430 |
2015 |
|
rs724159947
|
|
T |
0.700 |
GeneticVariation |
CLINVAR |
Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy.
|
25581430 |
2015 |
|
rs1057519766
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three out of 14 (21.4 %) C57BL/6J mice transplanted with FLT3-N676K-transduced primary hematopoietic progenitor cells developed acute leukemia (latency of 68, 77, and 273 days), while no hematological malignancy was observed in the control groups including FLT3-ITD.
|
26891877 |
2016 |
|
rs78245253
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Hence, we concluded GATA-2 L359 V is exclusively associated with CML progression but not other hematological malignancies and P250A is a new single nucleotide polymorphism.
|
19304323 |
2009 |
|
rs104894226
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We show here that the salient features of ALPS as well as a predisposition to hematological malignancies can be caused by a heterozygous germline Gly13Asp activating mutation of the NRAS oncogene that does not impair CD95-mediated apoptosis.
|
17517660 |
2007 |
|
rs148704956
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This study retrospectively examined the impact of a single-nucleotide polymorphism (rs2275913, G197A) in the IL-17 gene of a total 510 recipients with hematologic malignancies and their unrelated donors on the clinical outcomes in HLA-matched myeloablative (discovery study) and nonmyeloablative (validation study) BMT through the Japan Marrow Donor Program (JMDP).
|
21217785 |
2011 |